Abstract
Survivin is a relatively unique member of the inhibitor of apoptosis protein (IAP) family. It contains a single baculovirus IAP repeat (BIR) domain. It is involved in the control of cell cycle and inhibition of apoptosis. Survivin is of interest because it is specifically up-regulated in cancer cells and completely down-regulated and undetectable in normal adult tissues. Thus, survivin has proved to be a promising therapeutic target for normal anti-cancer therapy. Survivin protects the fast dividing tumor cells against default apoptosis to facilitate aberrant mitosis. Down-regulation of survivin with multiple approaches, suppress tumor progression and induce apoptosis on its own or in combination with chemotherapy and radiotherapy.
Keywords: Survivin, IAPs, Apoptosis, Caspases, Ribozyme, p53
Current Cancer Therapy Reviews
Title: Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Volume: 2 Issue: 1
Author(s): Zakir Khan, Pratiksha Bhadouria, Radha Gupta and Prakash S. Bisen
Affiliation:
Keywords: Survivin, IAPs, Apoptosis, Caspases, Ribozyme, p53
Abstract: Survivin is a relatively unique member of the inhibitor of apoptosis protein (IAP) family. It contains a single baculovirus IAP repeat (BIR) domain. It is involved in the control of cell cycle and inhibition of apoptosis. Survivin is of interest because it is specifically up-regulated in cancer cells and completely down-regulated and undetectable in normal adult tissues. Thus, survivin has proved to be a promising therapeutic target for normal anti-cancer therapy. Survivin protects the fast dividing tumor cells against default apoptosis to facilitate aberrant mitosis. Down-regulation of survivin with multiple approaches, suppress tumor progression and induce apoptosis on its own or in combination with chemotherapy and radiotherapy.
Export Options
About this article
Cite this article as:
Khan Zakir, Bhadouria Pratiksha, Gupta Radha and Bisen S. Prakash, Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene, Current Cancer Therapy Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339406777592113
DOI https://dx.doi.org/10.2174/157339406777592113 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer
Current Cancer Drug Targets Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets One-pot Synthesis and its Practical Application in Pharmaceutical Industry
Current Organic Synthesis The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science From Natural Products to Small Molecule Ketone Histone Deacetylase Inhibitors: Development of New Class Specific Agents
Current Pharmaceutical Design Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology Metastasis Suppressors: Basic and Translational Advances
Current Pharmaceutical Biotechnology Adenoviral Vectors for Cancer Gene Therapy
Current Genomics The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Neuronal Semaphorins Regulate a Primary Immune Response
Current Neurovascular Research Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets Antisense Strategies
Current Molecular Medicine Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors
Current Cancer Drug Targets Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets